Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
B&B PHARMA from Brussel, company number BE0666765726, closed financial year 2025 with a result of € 2,559 after tax. For that financial year B&B PHARMA recorded a gross margin of € 1,758 and equity of € -337,915. Compared with financial year 2024, the result moved from € 116,362 to € 2,559. The company is profitable. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ -337,915
▲ € 2,559 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2,559
▼ 98% vs 2024
Profit after tax over the fiscal year.
€ 2,646
▼ 23% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -356,515.
Debts at end 2025
€ 40,000
Loans from banks and other lenders, long and short.
€ 38,491
▼ 1% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 124
▼ 99% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 48,324 | € 96,682 | € 122,840 | € 1,758 | ▼ 99% |
| Profit after taxes | € 22,549 | € -82,710 | € 116,362 | € 2,559 | ▼ 98% |
| Equity | € -374,125 | € -456,835 | € -340,474 | € -337,915 | ▲ € 2,559 |
| Total debts | € 637,647 | € 559,161 | € 376,459 | € 373,158 | ▼ 1% |
| Cash | € 4,819 | € 18,975 | € 3,455 | € 2,646 | ▼ 23% |
| Retained profit | € -392,725 | € -475,435 | € -359,074 | € -356,515 | ▲ € 2,559 |
| Bank debt | € 226,589 | € 121,302 | € 40,000 | € 40,000 | |
| Balance sheet total | € 263,521 | € 102,325 | € 35,985 | € 35,243 | ▼ 2% |
Key figures of B&B PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to B&B PHARMA?
What happened at B&B PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 2,559 (▼ 98% vs 2024). Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 22,549 profit in 2022 to € 2,559 profit in 2025.
Best year ever: 2024, with € 116,362 profit.
A new publication or filing at B&B PHARMA? We notify you, reason included.
Follow B&B PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind B&B PHARMA are Richard Bontemps and Metin Bakar. Metin Bakar is also behind PHARMABAK, WEST PHARMA, "WESTLAND PHARMA", Pharma City 2 and BKR.
Directors
According to the 2025 annual accounts
Richard Bontemps
Director
Establishments
Establishment units
Physical locations of this company
Kruidtuinlaan 5a
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0666.765.726
- VAT number
- BE 0666.765.726
- Registered office
- Kruidtuinlaan 5a, 1000 Brussel
- Names & denominations
- B&B PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 November 2016
- Peppol
- Active · Active since 26 Nov 2025
- Activities · NACE
Activiteiten van kuuroorden, sauna’s en stoombaden
Sauna's, solaria, baden enz.
Detailhandel in cosmetica en toiletartikelen